SG Americas Securities LLC Trims Stock Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

SG Americas Securities LLC trimmed its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 45.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,025 shares of the company's stock after selling 6,694 shares during the quarter. SG Americas Securities LLC's holdings in Kymera Therapeutics were worth $323,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the company. Values First Advisors Inc. bought a new stake in shares of Kymera Therapeutics in the third quarter valued at about $61,000. Quarry LP acquired a new position in Kymera Therapeutics during the third quarter worth $95,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company's stock worth $114,000 after acquiring an additional 504 shares during the period. Integrated Advisors Network LLC purchased a new position in Kymera Therapeutics in the third quarter valued at $294,000. Finally, Thrivent Financial for Lutherans purchased a new position in shares of Kymera Therapeutics during the third quarter worth about $313,000.

Kymera Therapeutics Stock Performance

NASDAQ KYMR traded down $1.72 during trading hours on Friday, reaching $37.32. The company's stock had a trading volume of 300,779 shares, compared to its average volume of 489,423. The stock has a market cap of $2.42 billion, a PE ratio of -15.95 and a beta of 2.18. Kymera Therapeutics, Inc. has a fifty-two week low of $29.24 and a fifty-two week high of $53.27. The company's 50-day moving average is $41.46 and its two-hundred day moving average is $44.50.

Insider Transactions at Kymera Therapeutics

In related news, insider Ellen Chiniara sold 3,129 shares of the firm's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $41.75, for a total transaction of $130,635.75. Following the transaction, the insider now owns 54,826 shares of the company's stock, valued at approximately $2,288,985.50. This trade represents a 5.40 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 15.82% of the company's stock.

Analyst Upgrades and Downgrades

KYMR has been the subject of a number of research analyst reports. BMO Capital Markets initiated coverage on shares of Kymera Therapeutics in a report on Friday, December 6th. They issued a "market perform" rating and a $55.00 target price for the company. Leerink Partners reissued an "outperform" rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Friday, December 27th. BTIG Research initiated coverage on shares of Kymera Therapeutics in a report on Tuesday, December 10th. They set a "buy" rating and a $60.00 price target on the stock. Truist Financial reiterated a "buy" rating and set a $53.00 target price (down from $54.00) on shares of Kymera Therapeutics in a research report on Friday, November 1st. Finally, Guggenheim boosted their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the stock a "buy" rating in a research note on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $55.06.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.